NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
The bidirectional relationship between type 2 diabetes and (non-alcoholic fatty liver disease) NAFLD is indicated by the higher prevalence and worse disease course of one condition in the presence of the other, but also by apparent beneficial effects observed in one, when the other is improved. This...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/2/272 |
| _version_ | 1827343240974565376 |
|---|---|
| author | Simona Cernea |
| author_facet | Simona Cernea |
| author_sort | Simona Cernea |
| collection | DOAJ |
| description | The bidirectional relationship between type 2 diabetes and (non-alcoholic fatty liver disease) NAFLD is indicated by the higher prevalence and worse disease course of one condition in the presence of the other, but also by apparent beneficial effects observed in one, when the other is improved. This is partly explained by their belonging to a multisystemic disease that includes components of the metabolic syndrome and shared pathogenetic mechanisms. Throughout the progression of NAFLD to more advanced stages, complex systemic and local metabolic derangements are involved. During fibrogenesis, a significant metabolic reprogramming occurs in the hepatic stellate cells, hepatocytes, and immune cells, engaging carbohydrate and lipid pathways to support the high-energy-requiring processes. The natural history of NAFLD evolves in a variable and dynamic manner, probably due to the interaction of a variable number of modifiable (diet, physical exercise, microbiota composition, etc.) and non-modifiable (genetics, age, ethnicity, etc.) risk factors that may intervene concomitantly, or subsequently/intermittently in time. This may influence the risk (and rate) of fibrosis progression/regression. The recognition and control of the factors that determine a rapid progression of fibrosis (or its regression) are critical, as the fibrosis stages are associated with the risk of liver-related and all-cause mortality. |
| first_indexed | 2024-03-07T22:23:24Z |
| format | Article |
| id | doaj.art-02680d72304445b2a66b1a915950d1cb |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-07T22:23:24Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-02680d72304445b2a66b1a915950d1cb2024-02-23T15:24:49ZengMDPI AGLife2075-17292024-02-0114227210.3390/life14020272NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic InterplaySimona Cernea0Department M3, Internal Medicine I, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, 540142 Târgu Mureş, RomaniaThe bidirectional relationship between type 2 diabetes and (non-alcoholic fatty liver disease) NAFLD is indicated by the higher prevalence and worse disease course of one condition in the presence of the other, but also by apparent beneficial effects observed in one, when the other is improved. This is partly explained by their belonging to a multisystemic disease that includes components of the metabolic syndrome and shared pathogenetic mechanisms. Throughout the progression of NAFLD to more advanced stages, complex systemic and local metabolic derangements are involved. During fibrogenesis, a significant metabolic reprogramming occurs in the hepatic stellate cells, hepatocytes, and immune cells, engaging carbohydrate and lipid pathways to support the high-energy-requiring processes. The natural history of NAFLD evolves in a variable and dynamic manner, probably due to the interaction of a variable number of modifiable (diet, physical exercise, microbiota composition, etc.) and non-modifiable (genetics, age, ethnicity, etc.) risk factors that may intervene concomitantly, or subsequently/intermittently in time. This may influence the risk (and rate) of fibrosis progression/regression. The recognition and control of the factors that determine a rapid progression of fibrosis (or its regression) are critical, as the fibrosis stages are associated with the risk of liver-related and all-cause mortality.https://www.mdpi.com/2075-1729/14/2/272liver fibrosistype 2 diabetesNAFLD |
| spellingShingle | Simona Cernea NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay Life liver fibrosis type 2 diabetes NAFLD |
| title | NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay |
| title_full | NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay |
| title_fullStr | NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay |
| title_full_unstemmed | NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay |
| title_short | NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay |
| title_sort | nafld fibrosis progression and type 2 diabetes the hepatic metabolic interplay |
| topic | liver fibrosis type 2 diabetes NAFLD |
| url | https://www.mdpi.com/2075-1729/14/2/272 |
| work_keys_str_mv | AT simonacernea nafldfibrosisprogressionandtype2diabetesthehepaticmetabolicinterplay |